Lilly has entered into a global licensing and collaboration agreement with Innovent Biologics securing exclusive rights outside Greater China to develop and commercialise multiple oncology and immunology candidates. Through the deal, which is valued at up to US$8.85 B, Innovent will lead discovery and early clinical development through Phase II while Lilly will assume global advancement and commercial execution. Extending a collaboration that has evolved over nearly a decade, the agreement further strengthens its oncology and immunology pipeline through cross-border innovation and long-term strategic value creation.